Home Stocks BIAF bioAffinity Technologies, Inc. (NASDAQ: BIAF) Healthcare · Diagnostics & Research
$2.11 +0.18 (+9.33%)
Last close · Nov 18, 2026 · NASDAQ USD
The Quantellect read. BIAF rose 9.33% in the Nov 18 session to $2.11. The borrow fee is 87.55%. Zero active firms cover the stock as of Nov 18, 2026; zero active firms with targets average $6.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Relative valuation Lower multiples than peers P/S 0.7× vs peer median 4.5×
Momentum Neutral RSI (14) 36.6 (overbought above 70, oversold below 30)
Short interest 10.6% of float FINRA settlement Oct 30, 2026
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open $2.06 Nov 18, 2026 session
Previous close $1.93 Nov 17, 2026 close
Day range $2.06 – $2.20 Nov 18, 2026 session
52-week range —
Volume 1.04K Nov 18, 2026 session
Average volume (30 calendar days) —
Market cap —
P/E (TTM) —
Forward P/E —
EPS (TTM) —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) —
Price history BIAF · nasdaq · USD
Last completed session: Nov 17, 2026
Split-adjusted · volume in shares
November 2026 · 12 completed sessions Date Open High Low Close Change Volume Nov 17 1.99 2.0531 1.90 1.93 −0.07−3.50% 67,866 Open 1.99 High 2.0531 Low 1.90 Nov 16 2.125 2.132 1.96 2.00 −0.20−9.090909% 74,099 Open 2.125 High 2.132 Low 1.96 Nov 13 2.3415 2.3501 2.17 2.20 −0.14−5.982906% 51,554 Open 2.3415 High 2.3501 Low 2.17 Nov 12 2.43 2.45 2.2901 2.34 −0.085−3.505155% 48,525 Open 2.43 High 2.45 Low 2.2901 Nov 11 2.37 2.60 2.23 2.425 +0.035+1.464435% 76,416 Open 2.37 High 2.60 Low 2.23 Nov 10 2.47 2.49 2.37 2.39 +0.13+5.752212% 82,080 Open 2.47 High 2.49 Low 2.37 Nov 9 2.65 2.90 2.25 2.26 −0.455−16.758748% 101,644 Open 2.65 High 2.90 Low 2.25 Nov 6 2.62 2.8245 2.62 2.715 +0.115+4.423077% 24,832 Open 2.62 High 2.8245 Low 2.62 Nov 5 2.96 2.971 2.541 2.60 −0.33−11.262799% 76,813 Open 2.96 High 2.971 Low 2.541 Nov 4 3.11 3.22 2.93 2.93 −0.26−8.15047% 52,563 Open 3.11 High 3.22 Low 2.93 Nov 3 2.99 3.20 2.965 3.19 +0.20+6.688963% 98,862 Open 2.99 High 3.20 Low 2.965 Nov 2 2.84 3.0564 2.84 2.99 +0.08+2.749141% 90,283 Open 2.84 High 3.0564 Low 2.84
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score 12 /100 Poor
Latest available: Nov 13, 2026 · updates irregularly
Each axis is a 0 to 100 percentile rank among equities
Liquidity 18 Short 91 Squeeze 32 Trend 2 Momentum 4 Valuation 62 Stability 3 What each one means Liquidity 18
Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.
Short 91
Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.
Squeeze 32
Higher scores reflect a higher published Squeeze score within equity peers.
Trend 2
Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.
Momentum 4
Higher scores reflect stronger 63- and 126-session total returns within equity peers.
Valuation 62
Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.
Stability 3
Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.
How the Q Score works → How BIAF compares with its industry Against 44 other US-listed Diagnostics & Research stocks
Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%
Strongest pointsLatest-quarter year-over-year sales growth was 19%, higher than 77% of 44 peers.Peer median 8.1% · As of Nov 17, 2026 Points of cautionTrailing-year net margin was -257.3%, with only 0% of 43 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026 Three-month return was -68.5%, with only 10% of 42 peers reporting a lower value.Peer median 4.7% · As of Nov 16, 2026 Current ratio was 1.51, with only 24% of 41 peers reporting a lower value.Peer median 2.63 · As of Nov 17, 2026 Valuation Lower multiples than peers
Metric BIAF Peer median
Profitability Profitability metrics are lower than most peers.
Metric BIAF Peer median
Growth Growth metrics are higher than most peers.
Metric BIAF Peer median
Quarterly sales growth, year over year 19.0% 8.1%
Higher than 77% of 44 peers
5-year sales growth rate — 7.8%
Not ranked: only 32 of 44 peers report it
Balance sheet Balance sheet metrics are lower than most peers.
Metric BIAF Peer median
Momentum Returns are lower than most peers.
Metric BIAF Peer median
How to read this The dot marks where BIAF ranks among its peers on each metric, from lowest (left) to highest (right). The tick in the middle marks the peer median.
Green marks a rank in the top 10% of peers, amber the bottom 10%. Valuation and balance-sheet metrics stay neutral because a high rank there is not better or worse.
A metric is ranked only when enough peers report it. Peers exclude this company. Percentages count peers with a strictly lower value; equal values do not count.
Lowest Median Highest
Compared with 44 other US-listed Diagnostics & Research stocks · fundamentals as of Nov 15, 2026 · prices as of Nov 16, 2026
Upcoming events — · Upcoming events not available
Analyst consensus No Coverage
0 Strong Buy
0 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 0 active firms as of Nov 18, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $6.00
Average $6.00
High $6.00
As of Nov 18, 2026 across 0 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −10.00 −8.00 −6.00 −4.00 −2.00 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 — −$5.89 —
Q2 2026 — −$0.64 —
Q1 2026 — −$0.81 —
Annual 2025 — −$8.66 —
Q3 2025 — −$4.74 —
Q2 2025 — −$0.17 —
Q1 2025 — −$0.16 —
Annual 2024 −$0.14 −$0.75 —
News and press releases Year All 2026 2025 Nov 11, 2026, 8:00 AM ET Nov 6, 2026, 5:40 PM ET Oct 29, 2026, 8:00 AM ET Jun 23, 2026, 3:46 PM ET All BIAF news → Company profile bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics
CEO Ms. Maria Zannes J.D.
Headquarters San Antonio, TX, United States
Employees 57
IPO date Sep 1, 2022
Sector Healthcare
Industry Diagnostics & Research Q Score 12 /100 Poor
Latest available: Nov 13, 2026 · updates irregularly
Each axis is a 0 to 100 percentile rank among equities
Liquidity 18 Short 91 Squeeze 32 Trend 2 Momentum 4 Valuation 62 Stability 3 What each one means Liquidity 18
Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.
Short 91
Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.
Squeeze 32
Higher scores reflect a higher published Squeeze score within equity peers.
Trend 2
Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.
Momentum 4
Higher scores reflect stronger 63- and 126-session total returns within equity peers.
Valuation 62
Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.
Stability 3
Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.
How the Q Score works → Upcoming events — · Upcoming events not available
Analyst consensus No Coverage
0 Strong Buy
0 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 0 active firms as of Nov 18, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $6.00
Average $6.00
High $6.00
As of Nov 18, 2026 across 0 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −10.00 −8.00 −6.00 −4.00 −2.00 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 — −$5.89 —
Q2 2026 — −$0.64 —
Q1 2026 — −$0.81 —
Annual 2025 — −$8.66 —
Q3 2025 — −$4.74 —
Q2 2025 — −$0.17 —
Q1 2025 — −$0.16 —
Annual 2024 −$0.14 −$0.75 —
Company profile bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics
CEO Ms. Maria Zannes J.D.
Headquarters San Antonio, TX, United States
Employees 57
IPO date Sep 1, 2022
Sector Healthcare
Industry Diagnostics & Research